Stocktoria
Phathom Pharmaceuticals, Inc. PHAT
Phathom Pharmaceuticals, Inc. (PHAT) earns a Piotroski F-score of 4/9 (mixed financial health). It does not currently pay a dividend. FY2025 revenue was $175.1M at a -126.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -1.34 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| PHAT | Phathom Pharmaceuticals, Inc. | 4/9 | — | — | +216.9% |
| CYRX | Cryoport, Inc. | 4/9 | 0.96 | 10.3 | +12.4% |
| SNDX | Syndax Pharmaceuticals Inc | 1/9 | -7.54 | — | +627.8% |
| STOK | Stoke Therapeutics, Inc. | 4/9 | 5.29 | — | +404.5% |
| MRVI | MARAVAI LIFESCIENCES HOLDINGS, INC. | 1/9 | 1.29 | — | -28.3% |
| RYTM | RHYTHM PHARMACEUTICALS, INC. | 5/9 | -6.24 | — | +45.8% |
| LQDA | Liquidia Corp | 3/9 | -4.36 | — | +1031.2% |
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
FAQ
Is PHAT financially healthy?
Phathom Pharmaceuticals, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak).
Does PHAT pay a dividend?
No, Phathom Pharmaceuticals, Inc. does not currently pay a dividend.
How profitable is PHAT?
In FY2025, Phathom Pharmaceuticals, Inc. had a net margin of -126.3%.
What is the analyst price target for PHAT?
The average Wall-Street price target for Phathom Pharmaceuticals, Inc. is $23.70, about 158.5% above the recent price, from 10 analysts (consensus: strong buy).
Is PHAT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Phathom Pharmaceuticals, Inc.: a Piotroski F-score of 4/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.